Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | Feasibility of BCMA-directed CAR-T therapy in R/R AL amyloidosis

Moshe Gatt • 5 Sep 2022
ISA 2022
Amyloidosis Rare Diseases CAR-T HBI0101

Moshe Gatt, MD, Hadassah Medical Center, Jerusalem, Israel, discusses the results of a Phase I study evaluating the feasibility of HBI0101 (NCT04720313), a novel academic BCMA-directed CAR-T therapy for the treatment of relapsed/refractory (R/R) amyloidosis. In addition to a high rate of complete remission and MRD negativity, patients had impressive organ responses, with a significant reduction in cardiac proBNP and disappearance of proteinuria. Nevertheless, some patients experienced cytokine release syndrome (CRS) and congestive heart failure, and it is still necessary to determine the durability of these CAR-Ts. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals